Myocardial perfusion reserve and contractile pattern after beta-blocker therapy in patients with idiopathic dilated

R H J A Slart1, R A Tio, P A van der Vleuten

  • 1Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, PO Box 30001, 9700 RB Groningen, The Netherlands. r.h.j.a.slart@nucl.umcg.nl

Insights

Idiopathic Dilated Cardiomyopathy (IDC) patients responding to beta-blockers show improved myocardial perfusion reserve. Non-responders experience a decrease in perfusion reserve, correlating with worsening left ventricular function.

Area of Science:

  • Cardiology
  • Nuclear Cardiology
  • Cardiovascular Imaging

Background:

  • Idiopathic Dilated Cardiomyopathy (IDC) is linked to myocardial oxygen supply-demand imbalance.
  • Subclinical ischemia may worsen left ventricular (LV) function in IDC.
  • Beta-blockers are standard therapy, but patient response varies.

Purpose of the Study:

  • To identify differences in regional myocardial perfusion reserve (MPR) and contractile function between beta-blocker responders and non-responders in IDC.
  • To assess if MPR and LV function changes correlate with beta-blocker treatment outcomes.

Main Methods:

  • Patients with newly diagnosed IDC underwent baseline and stress Positron Emission Tomography (PET) for MPR and dobutamine stress Magnetic Resonance Imaging (MRI) for contractile function.
  • PET and MRI were repeated after 6 months of maximal beta-blocker therapy.
  • Myocardial perfusion reserve (MPR) and wall motion score (WMS) were evaluated using a 17-segment model.

Main Results:

  • Responders showed significant improvement in MPR (1.56 to 1.93) and wall motion scores.
  • Non-responders exhibited a non-significant decrease in MPR (1.98 to 1.61) and no change in wall motion.
  • A significant correlation was found between changes in MPR and LVEF; decreased MPR was associated with decreased LVEF.

Conclusions:

  • In IDC, improved LV function with beta-blockers correlates with enhanced regional perfusion.
  • Deterioration of LV function in IDC patients on beta-blockers is associated with reduced myocardial perfusion reserve.
  • MPR assessment may help differentiate treatment response in IDC.
Abstract

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...